Effect of nutritional supplements in the treatment of polycystic ovary syndrome

Integration of transcriptome and molecular docking to identify effective nutritional supplements in the treatment of polycystic ovary syndrome

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240407061432N1

Enrollment

Registered

2024-04-17

Start date

2024-04-20

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome (PCOS). Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: 2000 units of vitamin D from Dana Pharma are prescribed for women recently diagnosed with PCOS and no history of supplement or drug use. They are asked to consume t

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Woman aged 18-40 with PCOS confirmed by a gynecologist (new case)

Exclusion criteria

Exclusion criteria: Pregnant women Menopausal women Women who underwent oophorectomy or hysterectomy Women using oral contraceptive pills (OCP) Women who previously used dietary supplements Lack of interest in study participation Age 40 years

Design outcomes

Primary

Measure	Time frame
The ratio of changes in target gene expression. Timepoint: Gene expression measured at the beginning of the study (before the intervention) and 2 months after starting the candidate food supplement (Vit D). Method of measurement: Real- Time RT-PCR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahram Nekoeian

Esfahan University of Medical Sciences

Nekoeian_sh@yahoo.com+98 31 3237 1103

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026